These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 14962766)

  • 1. Strategies for converting allergens into hypoallergenic vaccine candidates.
    Vrtala S; Focke-Tejkl M; Swoboda I; Kraft D; Valenta R
    Methods; 2004 Mar; 32(3):313-20. PubMed ID: 14962766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular approaches for new vaccines against allergy.
    Niederberger V; Valenta R
    Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy.
    Valenta R; Vrtala S; Focke-Tejkl M; Bugajska-Schretter ; Ball T; Twardosz A; Spitzauer S; Grönlund H; Kraft D
    Biol Chem; 1999; 380(7-8):815-24. PubMed ID: 10494830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From allergen genes to new forms of allergy diagnosis and treatment.
    Vrtala S
    Allergy; 2008 Mar; 63(3):299-309. PubMed ID: 18269675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of antigen-specific immunotherapy of allergy.
    Valenta R
    Nat Rev Immunol; 2002 Jun; 2(6):446-53. PubMed ID: 12093011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6.
    Linhart B; Mothes-Luksch N; Vrtala S; Kneidinger M; Valent P; Valenta R
    Biol Chem; 2008 Jul; 389(7):925-33. PubMed ID: 18627317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.
    Linhart B; Hartl A; Jahn-Schmid B; Verdino P; Keller W; Krauth MT; Valent P; Horak F; Wiedermann U; Thalhamer J; Ebner C; Kraft D; Valenta R
    J Allergy Clin Immunol; 2005 May; 115(5):1010-6. PubMed ID: 15867859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic allergen modification in the development of novel approaches to specific immunotherapy.
    Mutschlechner S; Deifl S; Bohle B
    Clin Exp Allergy; 2009 Nov; 39(11):1635-42. PubMed ID: 19624521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergen mimotopes.
    Riemer A; Scheiner O; Jensen-Jarolim E
    Methods; 2004 Mar; 32(3):321-7. PubMed ID: 14962767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
    Crameri R
    Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotechnology-based allergy diagnosis and vaccination.
    Bhalla PL; Singh MB
    Trends Biotechnol; 2008 Mar; 26(3):153-61. PubMed ID: 18222557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
    Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
    Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergy testing: the role of recombinant allergens.
    Mothes N; Valenta R; Spitzauer S
    Clin Chem Lab Med; 2006; 44(2):125-32. PubMed ID: 16475895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for the development of safe and effective DNA vaccines for allergy treatment.
    Hartl A; Weiss R; Hochreiter R; Scheiblhofer S; Bauer R; Valenta R; Ferreira F; Leitner W; Thalhamer J
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):279-98; discussion 299. PubMed ID: 15119049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.
    Valenta R; Linhart B; Swoboda I; Niederberger V
    Allergy; 2011 Jun; 66(6):775-83. PubMed ID: 21352238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of IgE binding to short peptides for the allergenic activity of food allergens.
    Albrecht M; Kühne Y; Ballmer-Weber BK; Becker WM; Holzhauser T; Lauer I; Reuter A; Randow S; Falk S; Wangorsch A; Lidholm J; Reese G; Vieths S
    J Allergy Clin Immunol; 2009 Aug; 124(2):328-36, 336.e1-6. PubMed ID: 19596143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latex allergy: a model for therapy.
    Rolland JM; O'Hehir RE
    Clin Exp Allergy; 2008 Jun; 38(6):898-912. PubMed ID: 18498539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines.
    Walgraffe D; Mattéotti C; El Bakkoury M; Garcia L; Marchand C; Bullens D; Vandenbranden M; Jacquet A
    J Allergy Clin Immunol; 2009 May; 123(5):1150-6. PubMed ID: 19152967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.